8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES S. Bruno, J.M. Vierling, R. Esteban, L.M. Nyberg, H. Tanno, J.K. Albrecht, C.A. Brass, N. Boparai, V. Sniukiene, M. Burroughs. A.O. Fatebenefratelli e Oftalmico, Milan, Italy; Baylor College of Medicine, Houston, TX, USA; Vall d’Hebron Hospital, Barcelona, Spain; Kaiser Permanente, San Diego, CA, USA; Hospital Provincial del Centenario, Rosario, Argentina; Merck, Whitehouse Station, NJ, USA E-mail: savino.bruno@fbf.milano.it